Filing Details

Accession Number:
0001140361-24-039821
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-30 21:02:08
Reporting Period:
2024-08-29
Accepted Time:
2024-08-30 21:02:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1368514 Adma Biologics Inc. ADMA Biological Products, (No Disgnostic Substances) (2836) 562590442
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1542519 B Jerrold Grossman C/O Adma Biologics, Inc.
465 State Route 17
Ramsey NJ 07446
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-29 118,861 $3.66 586,166 No 4 M Direct
Common Stock Acquisiton 2024-08-29 9,000 $5.96 595,166 No 4 M Direct
Common Stock Acquisiton 2024-08-29 9,000 $10.80 604,166 No 4 M Direct
Common Stock Disposition 2024-08-29 136,861 $17.27 467,305 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Disposition 2024-08-29 118,861 $3.66 118,861 $3.66
Common Stock Common Stock Disposition 2024-08-29 9,000 $5.96 9,000 $5.96
Common Stock Common Stock Disposition 2024-08-29 9,000 $10.80 9,000 $10.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2027-06-06 No 4 M Direct
0 2026-01-28 No 4 M Direct
0 2025-01-30 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 22,857 Indirect See Footnote
Common Stock 31,381 Indirect See Footnote
Common Stock 38,294 Indirect See Footnote
Common Stock 175 Indirect See Footnote
Footnotes
  1. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.595. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  2. Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 455,285 shares of common stock owned by the reporting person.
  3. These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood.
  4. These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
  5. These shares are owned by Genesis Foundation Inc. ("Genesis"). The reporting person is the President of Genesis.
  6. These shares are owned by the reporting person's wife.
  7. These options were granted on June 6, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on June 6, 2019.
  8. These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018.
  9. These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017.
  10. The Reporting Person is exercising these options due, in part, to their near-term expiration date.